Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

Faul,Margaret  ;McMillian ,Carl  ;Boulas,Pierre ;Saraceno,Reginaldo  ;Capizzi,Mary ;Cruz,Maureen ;

Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

Published on: October 15, 2020

Margaret M. Faul, Carl L. McMillian , Pierre Boulas, Reginaldo A. Saraceno, Mary Devlin Capizzi, Maureen T. Cruz

BioPharm International, BioPharm International-10-15-2020, Volume 2020 eBook, Issue 3

Pages: 45–49

The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.

Pharmaceutical development is a long, risky, and expensive process. In this highly competitive market, pharmaceutical companies are under constant pressure to deliver innovation via new therapeutics, new technology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this viewpoint, “precompetitive collaboration” may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercialization of a new product).

Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 45–49

Citation

When referring to this article, please cite it as M. M. Faul et al.,“Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation," BioPharm International Regulatory Sourcebook eBook (October 2020).